Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

Article content material

RESEARCH TRIANGLE PARK, N.C., Sept. 07, 2023 (GLOBE NEWSWIRE) — Fennec Prescribed drugs Inc. (NASDAQ:FENC; TSX: FRX), a industrial stage specialty pharmaceutical firm, at this time introduced that the Firm can be taking part in upcoming conferences. The administration staff can even host one-on-one investor conferences on the conferences.

Presentation Particulars:

Article content material

Occasion: H.C. Wainwright World Funding Convention in New York Metropolis
Date: September 12, 2023
Time: Firm Presentation at 1:30 PM ET

Article content material

Occasion: Cantor Fitzgerald World Healthcare Convention in New York Metropolis
Date: September 27, 2023
Time: Firm Presentation at 3:35 PM ET

For added data, please go to the investor relations part of the Firm’s web site at:
https://investors.fennecpharma.com/events-and-presentations/events

PEDMARK® (sodium thiosulfate injection)
PEDMARK^® is the primary and solely U.S. Meals and Drug Administration (FDA) authorised remedy indicated to cut back the chance of ototoxicity related to cisplatin therapy in pediatric sufferers with localized, non-metastatic, stable tumors. It’s a distinctive formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric sufferers. PEDMARK can be the one therapeutic agent with confirmed efficacy and security information with a longtime dosing paradigm, throughout two open-label, randomized Part 3 scientific research, the Scientific Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6.

Within the U.S. and Europe, it’s estimated that, yearly, greater than 10,000 kids could obtain platinum-based chemotherapy. The incidence of ototoxicity relies upon upon the dose and period of chemotherapy, and lots of of those kids require lifelong listening to aids. There may be at present no established preventive agent for this listening to loss and solely costly, technically troublesome, and sub-optimal cochlear (internal ear) implants have been proven to offer some profit. Infants and younger kids that endure ototoxicity at vital levels of improvement lack speech language improvement and literacy, and older kids and adolescents lack social-emotional improvement and academic achievement.

Article content material

Article content material

PEDMARK has been studied by co-operative teams in two Part 3 scientific research of survival and discount of ototoxicity, COG ACCL0431 and SIOPEL 6. Each research have been accomplished. The COG ACCL0431 protocol enrolled childhood cancers sometimes handled with intensive cisplatin remedy for localized and disseminated illness, together with newly identified hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma, medulloblastoma, and different stable tumors. SIOPEL 6 enrolled solely hepatoblastoma sufferers with localized tumors.

About Fennec Prescribed drugs

Fennec Prescribed drugs Inc. is a specialty pharmaceutical firm centered on the event and commercialization of PEDMARK^® and Pedmarqsi™ to cut back the chance of platinum-induced ototoxicity in pediatric sufferers. Additional, PEDMARK obtained FDA approval in September 2022 and European Fee Advertising Authorization in June 2023 for Pedmarqsi. PEDMARK has obtained Orphan Drug Exclusivity within the U.S. for seven years of market safety and Pedmarqsi has obtained Pediatric Use Advertising Authorization in Europe which incorporates eight years plus two years of knowledge and market safety. Fennec has a license settlement with Oregon Well being and Science College (OHSU) for unique worldwide license rights to mental property directed to sodium thiosulfate and its use for chemoprotection, together with the discount of danger of ototoxicity induced by platinum chemotherapy, in people. For extra data, please go to www.fennecpharma.com.

Article content material

Ahead Trying Statements

Aside from historic data described on this press launch, all different statements are forward-looking. Phrases akin to “imagine,” “anticipate,” “plan,” “anticipate,” “estimate,” “intend,” “could,” “will,” or the damaging of these phrases, and comparable expressions, are supposed to establish forward-looking statements. These forward-looking statements embrace statements about our enterprise technique, timeline, and different targets, plans and prospects, together with our commercialization plans respecting PEDMARK^®, the market alternative for and market affect of PEDMARK^®, its potential affect on sufferers and anticipated advantages related to its use, and potential entry to additional funding after the date of this launch. Ahead-looking statements are topic to sure dangers and uncertainties inherent within the Firm’s enterprise that would trigger precise outcomes to differ, together with the dangers and uncertainties that regulatory and guideline developments could change, scientific information and/or manufacturing capabilities might not be ample to fulfill regulatory requirements or receipt of required regulatory clearances or approvals, scientific outcomes might not be replicated in precise affected person settings, unexpected international instability, together with political instability, or instability from an outbreak of pandemic or contagious illness, such because the novel coronavirus (COVID-19), or surrounding the period and severity of an outbreak, safety supplied by the Firm’s patents and patent purposes could also be challenged, invalidated or circumvented by its opponents, the out there marketplace for the Firm’s merchandise is not going to be as massive as anticipated, the Firm’s merchandise will be unable to penetrate a number of focused markets, revenues is not going to be ample to fund additional improvement and scientific research, our capacity to acquire essential capital when wanted on acceptable phrases or in any respect, the Firm could not meet its future capital necessities in several nations and municipalities, and different dangers detailed every now and then within the Firm’s filings with the Securities and Trade Fee together with its Annual Report on Kind 10-Okay for the 12 months ended December 31, 2022. Fennec disclaims any obligation to replace these forward-looking statements besides as required by regulation.

For a extra detailed dialogue of associated danger components, please discuss with our public filings out there at www.sec.gov and www.sedar.com.

For additional data, please contact:

Buyers:
Robert Andrade
Chief Monetary Officer
Fennec Prescribed drugs Inc.
(919) 246-5299

Media:
Elixir Well being Public Relations
Lindsay Rocco
(862) 596-1304
lrocco@elixirhealthpr.com

Article content material